Tot Biopharm receives China regulatory approval for a bevacizumab biosimilar and Fujifilm moves forward with plans for a Suzhou Innovation and Collaboration Center.
An industrialized center northwest of Shanghai, China, was the source of a few items of biosimilars news this week.
Tot Biopharm
Suzhou, China-based Tot Biopharm said it has been granted regulatory approval for a bevacizumab biosimilar (Pusintin) by China’s National Medical Products Administration.
Pusintin (TAB008; injectable) is now approved for the treatment of patients with advanced metastatic or recurrent nonsquamous non–small cell lung cancer and metastatic colorectal cancer.
Bevacizumab reduces tumor-supporting blood vessels by targeting vascular endothelial growth factor. Tot Pharma cited pharmaceutical studies and nonclinical and clinical studies demonstrating that Pusintin is equivalent to the reference product, Avastin.
In China, bevacizumab is also approved for treatment of glioblastoma multiforme, hepatocellular carcinoma, ovarian cancer, and cervical cancer. Tot Pharma has commercial-scale manufacturing operations in Suzhou Industrial Park.
Fujifilm Innovation Center
With the growth of biosimilar markets and the demand for more affordable drugs, the market for cell culture development services is growing in China. Biosimilars are made from living organisms, and cell cultures are necessary for development of these therapeutics.
Fujifilm Irvine Scientific, of Santa Ana, California, said it will establish an Innovation and Collaboration Center in Suzhou New District where employees can design upstream cell culture processes for customers’ biomanufacturing needs.
“In the past decade, the world has seen rapid growth in China’s biopharmaceutical, vaccine, cell and gene therapy markets. The speed of approval of biosimilar drugs and investment by the government to make more affordable drugs available to its people is accelerating that growth,” the company said in a statement. Fujifilm said the market for cell culture media is anticipated to grow at an annual rate of 20%.
“The Innovation and Collaboration Center will incorporate advanced cell culture automation and analysis into process and media development to enable highly accurate evaluation and identification of optimal upstream cell culture processes,” Fujifilm said.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.